title: Efficacy and safety of different doses of tirofiban combined with ticagrelor on diabetic patients with AMI receiving in emergency percutaneous coronary intervention (PCI).
abstract: OBJECTIVE
  The aim of this study was to investigate the efficacy and safety of dual antiplatelet drugs combined with different doses of tirofiban on diabetic patients with acute myocardial infarction (AMI) receiving emergency percutaneous coronary intervention (PCI).
  
  
  METHODS
  158 diabetic patients with AMI undergone emergency PCI were randomly divided into three groups: Group A (53 cases) as the control group-dual anti-platelet agents (aspirin + ticagrelor); Group B (52 cases)-dual anti-platelet agents + conventional dose of tirofiban [10 μg/kg by PCI and 0.15 μg/(kg·min) by continue venous pump for 24 h]; Group C (53 cases)-dual antiplatelet agents + half-dose tirofiban [10 μg/kg by PCI and 0.075 μg/(kg·min) by continue venous pump for 24 h].
  
  
  RESULTS
  Compared with group A, thrombolysis in myocardial infarction 3 (TIMI3) blood flow and TIMI myocardial perfusion grade 3 (TMPG3) myocardial perfusion of patients in group B and group C after PCI was significantly higher (P < 0.05), the average day of hospitalization was significantly shorter (P < 0.05), reinfarction during hospitalization, post-infarction angina, severe arrhythmia, the incidence of cardiac function above KillipIII level was significantly lower (P < 0.05). And the differences between group B and C was not statistically significant (P > 0.05). Severe bleeding and moderate incidence of bleeding in group B was significantly higher than that in group A and group C (P < 0.05).
  
  
  CONCLUSIONS
  Based on combination of dual the anti-platelet agents and ticagrelor for diabetic patients with AMI receiving PCI, the combination of half-dose tirofiban can effectively improve TIMI flow and TMPG myocardial tissue perfusion, and reduce the incidence of major adverse cardiac events (MACE) and severe bleeding.
authors.affiliation: Department of Cardiology, People's Hospital of Zhengzhou, Southern Medical University Zhengzhou 45002, Hean, China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Liu
authors.affiliation: Department of Cardiology, People's Hospital of Zhengzhou, Southern Medical University Zhengzhou 45002, Hean, China.
authors.forename: Hengliang
authors.initials: H
authors.lastname: Liu
authors.affiliation: Department of Cardiology, People's Hospital of Zhengzhou, Southern Medical University Zhengzhou 45002, Hean, China.
authors.forename: Zhenxuan
authors.initials: Z
authors.lastname: Hao
authors.affiliation: Department of Cardiology, People's Hospital of Zhengzhou, Southern Medical University Zhengzhou 45002, Hean, China.
authors.forename: Guoying
authors.initials: G
authors.lastname: Geng
authors.affiliation: Department of Cardiology, People's Hospital of Zhengzhou, Southern Medical University Zhengzhou 45002, Hean, China.
authors.forename: Qi
authors.initials: Q
authors.lastname: Chen
authors.affiliation: Department of Cardiology, People's Hospital of Zhengzhou, Southern Medical University Zhengzhou 45002, Hean, China.
authors.forename: Wenjie
authors.initials: W
authors.lastname: Han
authors.affiliation: Department of Cardiology, People's Hospital of Zhengzhou, Southern Medical University Zhengzhou 45002, Hean, China.
authors.forename: Kailong
authors.initials: K
authors.lastname: Jia
authors.affiliation: Department of Cardiology, People's Hospital of Zhengzhou, Southern Medical University Zhengzhou 45002, Hean, China.
authors.forename: Yuxin
authors.initials: Y
authors.lastname: Zhou
keywords: Diabetes; acute myocardial infarction; anti-platelet; bleeding; complications; primary percutaneous coronary intervention